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Clinical and financial burdens of secondary level care in 
a public sector antiretroviral roll-out setting (G F Jooste 
Hospital)
Sebastian Kevany, Graeme Meintjes, Kevin Rebe, Gary Maartens, Susan Cleary
To limit the public health consequences of HIV/AIDS, the 
South African government implemented a comprehensive 
treatment programme in April 2004.1 While antiretroviral 
therapy (ART) dramatically increases life expectancy for 
infected individuals,2,3 there is often significant morbidity and 
mortality among patients with advanced HIV infection who 
start ART, and care is required after treatment has failed.4 
Expanding the ART programme requires increased health 
care system capacity, including that of secondary hospitals, 
to provide treatment at the appropriate scale and without 
crowding out other essential health services.
The introduction of ART has resulted in interventions 
increasingly aimed at aggressively treating opportunistic 
infections and resuscitating patients with advanced HIV so that 
they may benefit from longer-term ART. The increased survival 
time of patients on ART will probably result in higher levels 
of demand for secondary hospital treatment and increased 
need for management of antiretroviral (ARV)-related toxicity 
and immune reconstitution inflammatory syndromes (IRIS). 
These treatment requirements can be expected to increase in 
proportion to the level and scale of the national ART roll-out. 
To ensure that South African secondary level health services 
are not overburdened in caring for these patients, specific 
operational and financial provisions need to be made.
Despite these considerations, current operational and 
financial planning for the ARV roll-out is focused on dedicated 
ARV clinics, and the cost of secondary level care and referral 
services is excluded from the Treasury’s Conditional Grants 
for HIV and AIDS.5 In the Western Cape province, while 
many patients are initiated and managed on ART at the 
primary level, the development of complications frequently 
requires referral to secondary hospitals. Secondary facilities 
therefore also face significant resource demands to investigate 
and treat patients on or preparing for ART and presenting 
with opportunistic infections, IRIS, and drug side-effects. 
This situation is exacerbated by the fact that most patients 
commencing ART have advanced immunosuppression, with a 
median CD4 count of 43 cells/µl recorded at ART initiation in 
Khayelitsha,6 although this level has risen with expanded ART 
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Background. Antiretroviral therapy (ART) is being extended 
across South Africa. While efforts have been made to assess 
the costs of providing ART via accredited service points, little 
information is available on its downstream costs, particularly 
in public secondary level hospitals.
Objectives. To determine the cost of care for inpatients and 
outpatients at a dedicated antiretroviral referral unit treating 
and caring for antiretroviral-related conditions in a South 
African peri-urban setting; to identify key epidemiological 
cost drivers; and to examine the associated clinical and 
outcome data.
Methods. A prospective costing study on 48 outpatients and 25 
inpatients was conducted from a health system perspective. 
Incremental economic costs and clinical data were collected 
from primary sources at G F Jooste Hospital, Cape Town, over 
a 1-month period (March 2005).
Results. Incremental cost per outpatient was R1 280, and per 
inpatient R5 802. Costs were dominated by medical staff costs 
(62% inpatient and 58% outpatient, respectively). Infections 
predominated among diagnoses and costs – 55% and 67% 
respectively for inpatients, and 49% and 54% respectively 
for outpatients. Most inpatients and outpatients were judged 
by attending physicians to have improved or stabilised as a 
result of treatment (52% and 59% respectively).
Conclusions. The costs of providing secondary level care for 
patients on or immediately preceding ART initiation can 
be significant and should be included in the government’s 
strategic planning: (i) so that the service can be expanded to 
meet current and future needs; and (ii) to avoid crowding out 
other secondary level health services.
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access.7 Opportunistic infections and IRIS are much more likely 
in such patients.
Background and setting
This study was conducted at G F Jooste Hospital at Manenberg 
in Cape Town. G F Jooste is a public sector secondary hospital 
serving the Klipfontein Health District, and is administered by 
the Provincial Government of the Western Cape. An ARV clinic 
was established in the hospital in 2003, and secondary level 
referral services are provided for ARV clinics in its catchment 
area, namely Mitchell’s Plain, Gugulethu, Crossroads, Site 
B Khayelitsha and Nolungile ART clinics. G F Jooste serves 
a population of approximately 1.2 million people, including 
socially and economically disadvantaged communities. 
The unemployment rate in the Khayelitsha and Mitchell’s 
Plain areas has been estimated as 46.3%.8 The antenatal HIV 
prevalence in communities served by G F Jooste is up to 33% 
(Provincial Administration of the Western Cape, personal 
communication, 2005) and access to private health care is 
limited.
G F Jooste ARV referral unit
The G F Jooste ARV Referral Unit (ARU) was established in 
August 2004 in response to a high level of casualty admissions 
for patients on ART. It was designed to relieve demand on 
the hospital’s emergency department and as a referral service 
for complex cases, so that primary care clinics could focus on 
initiating large numbers of patients on ART. Significant and 
sustained levels of demand for this service prompted the unit’s 
expansion into an independent clinical service, providing 
specialist-directed investigation and treatment. During the 
study, the ARU was staffed by 2 infectious disease (ID) 
specialists (part-time), 2 medical officers, 1 registered nurse 
(providing outpatient care only), and an admissions clerk.
The ARU provides comprehensive outpatient care and 
inpatient consultation services to hospital patients in the 
medical wards. Any patient on ART developing clinical 
complications or any patient preparing for ART initiation 
may be referred. Outpatient consultations in the hospital’s 
outpatient department require the ad hoc use of examination 
rooms in the absence of designated facilities. Inpatient 
consultation is provided to patients in the medical wards, 
whose day-to-day care remains the responsibility of Medicine 
Department staff. Approximately 40% of ARU patients referred 
to the outpatient service require admission for inpatient care 
(unpublished audit).
ARU patients are referred from the G F Jooste ARV 
Clinic and the 5 local primary ART clinics for assessment 
and management. Potential referrals are initially discussed 
telephonically. Patients are triaged to: (i) immediate inpatient 
admission through the casualty department; (ii) an outpatient 
appointment at the ARU (generally within 48 hours); or (iii) 
continued primary care with specialist telephonic assistance. 
Outpatients are evaluated by the attending ARU clinician(s), 
and an investigation and management plan is developed, with 
the outcome being admission, follow-up at the ARU, or referral 
back to primary care.
Methods
Data were collected on all new and existing patients treated 
by the ARU from 1 to 31 March 2005. Information on inpatient 
length of stay after termination of the study period was 
collected during April and May 2005. All ARU patients had 
to be resident in the hospital catchment area, HIV-infected, 
>13 years of age, attending a designated ART clinic, and on or 
preparing for ART.
Incremental economic costs were assessed from a health 
systems perspective since the choice of costing perspective 
needs to be appropriate to the study question. Only costs 
incurred by the service provider or the State, and donated 
items that could fall within the provider’s budget in the future 
or in other settings, were included. While the alternative 
societal or patient perspectives elucidate a wider range of 
productivity, time, and indirect costs,9 these were excluded 
as they were not directly applicable to the study question. 
Incremental costs include patient-specific and medical staff 
costs, but exclude capital and overheads which have previously 
been assessed for G F Jooste.10
Clinical, resource use and treatment data were collected daily 
from ARU staff, with separate data capture forms for inpatients 
and outpatients. Patient-specific resource requirements 
were recorded and classified according to: (i) laboratory 
testing; (ii) imaging and radiology; (iii) medical and surgical 
procedures; (iv) medication; (v) intravenous fluids; (vi) medical 
consumables; and (vii) counselling services. A self-administered 
data capture form determined the level and distribution of 
clinical staff time. Clinical, investigation and treatment data 
were gathered according to a set of broad categories. Response 
to treatment was determined by the attending physician.
Laboratory costs were sourced from the hospital 
laboratory and National Health Laboratory Services (NHLS) 
estimates;11 pharmaceutical and intravenous fluid costs from 
the hospital pharmacy and the 2004 Community Health 
Services Organisation Drug Price Listings;12 the donated drug 
fluconazole cost was provided by the drug manufacturer; 
and imaging, radiology, medical and surgical procedure costs 
from the 2005 South African Uniform Patient Fee Schedule13 
and from the hospital’s finance department. All procedures 
unavailable at G F Jooste Hospital and conducted at Groote 
Schuur tertiary hospital were included. Medical and non-
medical consumable costs were sourced from the hospital 
supplies department. Counselling costs were provided by the 
Lifeline HIV Counselling Service, which manages G F Jooste 
counsellors. Other medical staff costs were provided by the 
hospital finance department, including benefits, scarce skills 
bonuses, commuted overtime, pension fund and medical aid 
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contributions. All costs are presented in South African rands at 
2005 rates.
A bottom-up, micro-costing procedure was employed for 
all patient-specific costs.14 Total costs across each costing 
category were assessed for each outpatient visit and inpatient 
admission. Average patient-specific costs per outpatient visit 
and per inpatient day were calculated by dividing costs by 
total outpatient visits and inpatient days, respectively. Total 
monthly clinical personnel costs were calculated by combining 
data on clinical staff time distribution with associated monthly 
salary figures. The allocation of shared personnel costs was 
based on accepted economic evaluation allocation procedures.15 
Monthly medical staff costs were then divided by total 
outpatient visits and inpatient days to determine total cost per 
outpatient visit and per inpatient day. Patient-specific costs 
(including imaging, laboratory testing, medication, procedures 
and counselling costs) were linked to diagnoses on a patient-
by-patient basis during the data collection process. Data 
sorting, cleaning and analysis were performed using EXCEL 
Version 9.0 (Seattle, Washington: 2000).
Results
Information on 48 new or existing outpatients and 25 new or 
existing inpatients (approximately 3.3% of those currently on 
ART in the referral area – information from provincial HIV 
directorate) was collected. A total of 63 outpatient visits and 
240 inpatient days were recorded. Inpatients were followed up 
until final date of discharge (Table I). A high proportion were 
female and between 20 and 30 years of age; mean age was 36 
years for outpatients at date of visit, and 34 years for inpatients 
at date of admission; 21 (44%) of 48 outpatients were diagnosed 
as WHO HIV clinical stage 4, and 9 (19%) presented with a CD4 
count <50 cells/µl; the mean outpatient CD4 count was 175 
cells/µl; 22 (88%) of 25 inpatients were diagnosed as clinical 
stage 4, and 52% presented with a CD4 count <50 cells/µl; the 
mean inpatient CD4 count was 78 cells/µl.
Of the outpatients, 33 (69%) were receiving ART and 14 
(29%) were preparing for ART initiation. Among those on ART, 
the median time from initiation was 8 months. For inpatients, 
16 (64%) were receiving ART and 7 (28%) were preparing for 
treatment initiation. Among those on ART, the median time 
from initiation was 2 months. One outpatient and 2 inpatients 
had interrupted ART treatment.
The mean length of inpatient stay was 14.6 days (this figure 
includes all inpatient days accrued in advance and after 
termination of the study period (365 inpatient days)). Average 
inpatient length of stay during the 1-month study period was 
9.6 days (240 days); 7 inpatients (28%) were hospitalised for 
7 days or less, 14 (56%) were admitted for 7 - 21 days, and a 
further 4 patients (16%) for >3 weeks. The average outpatient 
length of visit was 47 minutes.
Patients frequently presented with multiple diagnoses, and 
a total of 75 outpatient diagnoses and 36 inpatient diagnoses 
were recorded; infections dominated (55% inpatient, 49% 
outpatient), tuberculosis being a high proportion of inpatient 
and outpatient infection diagnoses. ARV drug toxicities were 
infrequent in inpatients (2 diagnoses, or 6% of all inpatient 
diagnoses) compared with outpatients (18 diagnoses or 24%) 
(Table II).
Table I. Patient characteristics
      Inpatients          Outpatients
            (%)            N=25 (%)         N=48
Gender
Male            24.0              6  23.0  11
Female            76.0              19 77.0  37
Total            100.0            25 100.0  48
Age group
20 - 30            44.0              11 33.3  16
30 - 40            36.0              9  37.5  18
40 - 50            8.0               2  20.8  10
>50            8.0               2  6.3  3
Unknown           4.0               1  2.1  1
Total            100.0            25 100.0  48
WHO clinical
stage
Stage 1            0.0               0  2.1  1
Stage 2            0.0               0  6.3  3
Stage 3            12.0              3  47.9  23
Stage 4            88.0              22 43.8  21
Total            100.0            25 100.0  48
Current CD4 
count (cells/µl)
>200            4.0               1  47.9  23
50 - 200           20.0              5  25.0  12
<50            52.0              13 18.8  9
Unknown           24.0              6  8.3  4
Total            100.0            25 100.0  48
ART status
Receiving           64.0              16 68.8  33
Preparatory           28.0              7  29.2  14
period
Interrupted           8.0               2  2.0  1
Total            100.0            25 100.0  48
ART regimen
3TC/D4T/efavirenz      48.0              12 41.7  20
3TC/D4T/nevirapine    16.0              4  8.3  4
3TC/AZT/efavirenz      0.0               0  6.3  3
3TC/AZT/nevirapine   0.0               0  6.3  3
Kaletra-based           4.0               1  4.2  2
Not applicable           24.0              6  29.2  14
Unknown           8.0               2  4.2  2
Total            100.0            25 100.0  48
Time since ART 
initiation (mo.)
0 - 3            40.0              10 10.4  5
4 - 6            8.0               2  16.7  8
7 - 9            12.0              3  12.5  6
10 - 12            0.0               0  14.6  7
>12            8.0               2  10.4  5
Not applicable           28.0              7  29.2  14
Unknown           4.0               1  6.3  3
Total            100.00           25 100.0  48
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Outpatient outcomes were based on the results of each 
outpatient visit, rather than individual patients. A high 
proportion of inpatients and outpatients either improved with 
treatment or were stabilised (Table III).
Inpatient-specific and outpatient-specific costs were 
dominated by infections (67%; 54%). For inpatients, 30% of 
costs were related to the treatment of cryptococcal meningitis 
and 26% to tuberculosis treatment. For outpatients, 22% of 
costs were related to the treatment of tuberculosis, and 15% to 
bacterial pneumonia (Table II).
Patient-specific costs for inpatients and outpatients 
were dominated by laboratory tests, medical and surgical 
procedures, and imaging and radiology costs. Medication costs 
were a low proportion of total patient-specific costs, as most 
patients were supplied with ART by their primary care clinics 
(Table IV).
Laboratory testing costs were dominated by blood tests. 
Imaging and radiology costs were primarily accrued by CT 
scanning. Medication costs were dominated by non-ARV 
antimicrobials and ARV drugs. Medical and surgical procedure 
costs were dominated by ambulatory rather than theatre-based 
procedures, particularly lumbar punctures and upper gastro-
intestinal endoscopies.
Medical staff costs accounted for the highest proportion of 
total inpatient and outpatient costs, dominated by clinician 
costs, with medical officer costs accounting for a high level of 
outpatient staff costs (55%).
Costs per outpatient visit and per inpatient day are presented 
in Table IV. The total costs of inpatient care (R145 062) were 
49% higher than total outpatient costs (R97 084), and the cost of 
care per inpatient (R5 802) was approximately 4.5 times higher 
than the cost per outpatient (R1 280).
Discussion
Most patients presented with an opportunistic infection, 
reflecting the initiation of ART with low CD4 counts in our 
population and suggesting the need for further research 
into their expedited primary-level diagnosis. In particular, 
interventions that expedite the diagnosis and treatment of 
tuberculosis at the primary level may reduce associated 
morbidity and secondary level referral.
As the lamivudine (3TC), D4T and efavirenz/nevirapine 
regimen is the national treatment programme standardised 
Table II. Primary and secondary diagnoses and associated laboratory, imaging, medication, and procedure costs
                 % inpatient                % outpatient     
Primary diagnosis Secondary diagnosis            diagnoses       N      Cost (R)    % of cost         diagnoses         N     Cost (R)   % of cost
Antiretroviral Neuropathy  0.0        0      0.00         0.0  2.7      2       2 366.32   8.6
drug toxicities Drug-induced hepatitis 2.8        1      934.66         2.1  6.7      5       131.35   0.5
  Drug-induced skin rash 0.0        0      0.00         0.0  1.3      1       1 091.94   4.0
  Lactic acidosis  2.8        1      618.59         1.4  4.0      3       279.98   1.0
  Lipodystrophy  0.0        0      0.00         0.0  1.3      1       47.44   0.2
  Symptomatic  0.0        0      0.00         0.0  6.7      5       1 727.61   6.3
  hyperlactataemia
  Suspected hyperlactataemia  0.0        0      0.00         0.0  1.4      1       143.45   0.5
  (subsequently disproven)
Sub-total    5.6        2      1 553.25       3.5  24.1      18     5 788.09   21.0
Infections  Chronic diarrhoea  5.6        2      2 002.05       4.5  1.3      1       354.88   1.3
  Cryptococcal meningitis 16.5        6      13 145.37     29.7  4.0      3       234.56   0.8
  Oesophageal candidiasis 0.0        0      0.00         0.0  1.3      1       57.92   0.2
  Other: infection  5.6        2      2 672.20      6.0  10.7      8       3 211.66   11.6
  P. carinii pneumonia 0.0        0      0.00         0.0  1.3      1       298.62   1.1
  Bacterial pneumonia 0.0        0      0.00         0.0  6.7      5       4 262.92   15.4
  Toxoplasmosis  0.0        0      0.00         0.0  1.3      1       81.39   0.3
  Tuberculosis  27.7        10      11 618.45     26.3  21.4      16     6 159.83   22.3
  Viral hepatitis  0.0        0      0.00         0.0  1.3      1       147.57   0.5
Sub-total    55.4        20      29 438.07     66.6  49.3      37     14 809.35   53.6
Other  Kaposi’s sarcoma  13.9        5      3 566.81      8.1  0.0      0       0.00   0.0
  Lymphoma  2.8        1      874.52        2.0   0.0      0       0.00   0.0
  Deep-vein thrombosis 2.8        1      463.01        1.0  0.0      0       0.00   0.0
  Acute renal failure  8.3        3      2 583.05      5.8  0.0      0       0.00   0.0
  HIV encephalopathy 0.0        0      0.00         0.0  5.3      4       1 785.11   6.5
  HIV nephropathy  2.8        1      1 533.61      3.5  5.3      4       1 112.92   4.0
  Other: HIV-related  5.6        2      3 759.99      8.5  8.0      6       1 843.41   6.7
  Other: HIV-unrelated 2.8        1      442.79         1.0  8.0      6       2 276.20   8.2
Sub-total    39.0        14      13 223.78     29.9  26.6      20     7 017.64   25.4
Total     100.0        36      44 215.10    100.0  100.0      75     27 615.08   100.0
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first-line ART regimen, no relationship between specific drug 
use and the need for secondary level treatment can be inferred. 
Eighteen outpatient diagnoses (24%) and 2 inpatient diagnoses 
(6%) were related to ARV toxicities.
ARU patient outcomes showed reasonable improvement (31 
patients) or stabilisation (19 patients) because of investigations 
and treatment. The proportions of patients improving and 
stabilising were similar for inpatients and outpatients. Further 
research into the morbidity of patients commencing ART is 
required, to assist in planning and developing appropriate 
interventions. The increased costs of interventions for the 
earlier detection of HIV/AIDS may be offset by savings in 
secondary level treatment and care. The earlier patients are 
diagnosed, enrolled in HIV care and initiated on ART when 
indicated, the less likely are complications by opportunistic 
infections.
The mean length of stay for inpatients is higher than prior 
findings for HIV-positive patients at G F Jooste Hospital.16 
Because of improved ART availability, physicians may be less 
inclined than previously to send patients for palliative care. 
Average outpatient visit duration was higher than average 
primary-level consultation times for both ART and non-ART 
patients10 but was still <1 hour.
Treatment costs were dominated by medical staff costs, 
accounting for 58% of outpatient and 62% of inpatient costs, 
which supports the investment in medical staff. Vertical 
health system interventions, including the ARV roll-out, may 
frequently concentrate resources on the provision of short-term 
consumable items. Parallel and complementary investment in 
infrastructure and clinical personnel is also necessary.
The high proportion of inpatient and outpatient costs as a 
result of infections suggests that the treatment of infections is 
critical in secondary level care for ART patients, especially for 
tuberculosis, cryptococcal meningitis and bacterial pneumonia. 
Treatment of infections remains one of the most costly and 
complex aspects of HIV care.
Table III. Response to ARU treatment
         Inpatients                Outpatient
             (%)             N          visits (%)  N
Response to treatment
Improved           32.0              8             36.5 23
Stabilised           20.0              5             22.2 14
No change           12.0              3             20.6 13
Deteriorated           0.0               0             1.7 1
Died            16.0              4             0  0
Unknown           20.0              5             19.0 12
Total            100.0            25           100.0 63
Table IV. Treatment costs
    Outpatients         Inpatients
               Total                    Total 
             monthly    Allocation      Monthly      Cost per      Cost per      monthly      Allocation     Monthly     Cost per    Cost per
Category               cost            factor      cost          visit         outpatient        cost    factor         cost            day        inpatient
Consultant (1)*   7 798.05 0.40   3 119.22         49.51             64.98         7 798.05     0.60       4 678.83        19.50        187.15
Consultant (2)*   13 467.32 0.46   6 194.97         98.33             129.06       13 467.32     0.54       7 272.35        30.30        290.89
Medical             21 633.64 0.19   4 110.39         65.24             85.63         21 633.64     0.81       17 523.25      73.01        700.93
officer (1)
Medical             20 568.20 0.70   14 397.74        228.54           299.95       20 568.20     0.30       6 170.46        25.71        246.82
officer (2)
Nursing sister     6 002.19 1.00   6 002.19         95.27             125.05       0.00     0.00       0.00           0.00          0.00
Medical             N/A  N/A    N/A         N/A              N/A         37 380.00     1.00       37 380.00      155.75      1 495.20
ward staff
Sub-total         69 469.40     33 824.51        536.90           704.68       100 847.21         73 024.89      304.27      2 921.00
Laboratory          8 932.70 1.00   8 932.70         141.79           186.10        9 635.65     1.00       9 635.65        40.15        385.43
testing
Imaging +           7 423.92 1.00   7 423.92         117.84           154.67       5 468.12     1.00       5 468.12        22.78        218.72
radiology
Medication         3 553.70 1.00   3 553.70         56.41             74.04         4 841.47     1.00       4 841.47        20.17        193.66
Medical +           7 704.76 1.00   7 704.76         122.30          160.52       6 762.58     1.00       6 762.58        28.18        270.50
surgical
procedures
Intravenous       0.00 1.00   0.00         0.00              0.00           1 016.91     1.00       1 016.91        4.24          40.68
fluids
Consumables     0.00 1.00   0.00         0.00              0.00           16 381.27     1.00       16 381.27      68.26        655.25
Counselling†      0.00 1.00   0.00         0.00              0.00           109.10     1.00       109.10           0.45         4.36
Sub-total         27 615.08    27 615.08        438.33           575.31        44 215.10        44 215.10      184.23      1 768.60
Total            97 084.48    61 439.59        975.23           1 279.99     145 062.31        117 239.99     488.49      4 689.60
* Part-time consultants.
† Outpatient adherence counselling provided in primary care.
ORIGINAL ARTICLES
325
The mean CD4 count for outpatients was higher than for 
inpatients, and there were also lower total and per-patient 
costs of care per outpatient than per inpatient. This finding 
illustrates the importance of earlier diagnosis and initiation 
onto ART to avert these high inpatient costs. The difference in 
total costs between outpatients and inpatients suggests that 
earlier referral and easier access to referral services for ART 
patients should be provided, rather than allowing patients to 
become so ill that they require inpatient care.
Limitations
Cost analyses are required over a significant time period for 
meaningful results, and have been described as ‘complex, 
difficult and time-consuming to perform’.17 In costing a pilot 
project, costs must be determined without the assistance of 
a costing template or associated studies. Limitations on the 
availability of appropriate datasets can diminish the accuracy 
of cost analysis results. All key primary datasets for this 
research were sourced directly from G F Jooste Hospital.
Conclusion
Our study of the costs of secondary level treatment for patients 
on or preparing for ART provides policymakers, planners and 
health system administrators with information on the potential 
hidden impact of ARV treatment. While a dedicated ARU 
is one model for meeting the secondary level needs of these 
patients, and other models may be more integrated within 
existing services, many clinical and financial needs may be 
similar. It is essential to include these costs in the government’s 
strategic planning for HIV treatment and Treasury budgets, 
to ensure adequate quality of care. Costing data are critical to 
the resource allocation process;18 however, limited information 
is available on public sector expenditure required to meet the 
needs of HIV-infected patients across the continuum of care.19
This study neither undermines nor questions the 
affordability and viability of the ARV roll-out but complements 
studies on the costs of scaling up ART in South Africa.4,5,20 The 
results expedite research into technical and allocative efficiency 
in the South African health system and may be used by 
secondary hospitals to assess the resources required for these 
treatments. While local considerations may require variations 
on the G F Jooste model, this evaluation may assist in the 
delivery of specialised secondary care. Estimates of secondary 
level treatment costs may be useful in assessing the macro-
economic effects of HIV/AIDS in South Africa.
The successful implementation of the ARV treatment 
programme depends on a strengthened health system.21 
In assessing the viability of specific health interventions, 
policymakers must consider their impact at all levels of the 
health system. The load on secondary level HIV referral 
services will inevitably increase as the ART roll-out expands, 
as evidenced by the same ARU at G F Jooste which had 
approximately 250 outpatient visits per month during 2007 
(unpublished data). Costs of care are significantly higher for 
patients on ART in South Africa.22 The development of ARUs, 
specifically to assess and treat patients on or preparing for 
ART, and the expansion of associated secondary hospital 
services, should be considered in planning the national ARV 
roll-out. Only through the comprehensive assessment of 
resource requirements across the health system can vertical 
interventions be fully audited, and scarce resources be 
distributed appropriately.
We thank Nontobeko Dyakopu, Jane Kawadza, Cordelia Faleni and 
David Stead for their assistance with data collection.
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